Improved oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-3-4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl-urea
CA 2415131 A1 · Owner: Boehringer Ingelheim Pharmaceuticals, Inc. · Inventors: Cappola, Michael L.; Way, Susan; Gereg, George W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A formulation comprising, and process for preparing improved oral dosage , forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-4-(2-morpholin-4-ylethoxy)-naphthalen-1-yl-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-4-(2morpholin-4-yl-ethoxy)-naphthalen-1-yl-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-4-(2morpholin-4-yl-ethoxy)-naphthalen-1-yl-urea and oral bioavailability as well , as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 11, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 11, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 11, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.